In a prior study that evaluated three distinct clones, a monoclonal antibody (clone 16/S100P) demonstrated the most reliable performance, being positive in 95% of large-duct ICCA cases compared with 29% of small-duct ICCA cases [62]. This evidence concerns the gene S100P and infantile convulsions and choreoathetosis.